Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
The company's need to find another growth story is laid bare by a setback to its label expansion plans for Cabometyx.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Aveo gets Fotivda over the line in the US, but the market celebration looks misplaced.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.